CCDC33

Summary

CCDC33 (coiled-coil domain containing 33, HGNC:26552) is a protein-coding gene on chromosome 15q24.1, encoding Coiled-coil domain-containing protein 33 (Q8N5R6).

Predicted to be active in peroxisome.

Source: NCBI Gene 80125 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 173 total — 1 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_025055

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26552
Approved symbol	CCDC33
Name	coiled-coil domain containing 33
Location	15q24.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ32855, CT61, CC2D3
Ensembl gene	ENSG00000140481
Ensembl biotype	protein_coding
OMIM	618525
Entrez	80125

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 5 protein_coding, 5 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000268082, ENST00000321374, ENST00000398814, ENST00000558645, ENST00000558659, ENST00000558821, ENST00000559243, ENST00000560148, ENST00000560565, ENST00000561332, ENST00000563951, ENST00000635913

RefSeq mRNA: 3 — MANE Select: NM_025055 NM_001287181, NM_025055, NM_182791

CCDS: CCDS42058, CCDS42059, CCDS73753

Canonical transcript exons

ENST00000398814 — 19 exons

Exon	Start	End
ENSE00001729163	74243985	74244148
ENSE00001787271	74236326	74236740
ENSE00003993786	74330189	74330354
ENSE00003993787	74330663	74330751
ENSE00003993788	74262440	74262573
ENSE00003993789	74333881	74333967
ENSE00003993790	74330981	74331112
ENSE00003993791	74280668	74280801
ENSE00003993792	74272771	74272891
ENSE00003993793	74281778	74281849
ENSE00003993794	74271703	74271794
ENSE00003993795	74332679	74332845
ENSE00003993796	74331203	74331296
ENSE00003993797	74334975	74335088
ENSE00003993798	74279963	74280092
ENSE00003993799	74295754	74295948
ENSE00003993800	74268342	74268458
ENSE00003993801	74266678	74266787
ENSE00003993802	74335925	74336141

Expression profiles

Bgee: expression breadth broad, 100 present calls, max score 98.28.

FANTOM5 (CAGE): breadth broad, TPM avg 1.6921 / max 102.8402, expressed in 377 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
147673	0.7892	244
147672	0.7073	247
147682	0.0433	24
147676	0.0406	9
147674	0.0284	14
147678	0.0273	5
147681	0.0193	9
147677	0.0160	3
147680	0.0150	7
147679	0.0057	2

Top tissues by expression

120 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	98.28	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	91.90	gold quality
left testis	UBERON:0004533	85.22	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.88	gold quality
testis	UBERON:0000473	84.75	gold quality
right testis	UBERON:0004534	84.73	gold quality
fallopian tube	UBERON:0003889	83.68	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.98	gold quality
adrenal tissue	UBERON:0018303	72.62	gold quality
left uterine tube	UBERON:0001303	68.15	gold quality
right lung	UBERON:0002167	65.74	gold quality
sural nerve	UBERON:0015488	64.40	silver quality
endocervix	UBERON:0000458	63.48	gold quality
pituitary gland	UBERON:0000007	61.58	gold quality
placenta	UBERON:0001987	59.38	gold quality
adenohypophysis	UBERON:0002196	58.52	gold quality
endometrium	UBERON:0001295	58.33	gold quality
adrenal gland	UBERON:0002369	57.34	gold quality
uterine cervix	UBERON:0000002	56.71	gold quality
right adrenal gland	UBERON:0001233	56.22	gold quality
left adrenal gland	UBERON:0001234	56.21	gold quality
stromal cell of endometrium	CL:0002255	55.74	gold quality
left adrenal gland cortex	UBERON:0035825	55.64	gold quality
lung	UBERON:0002048	55.13	gold quality
right adrenal gland cortex	UBERON:0035827	54.93	gold quality
hypothalamus	UBERON:0001898	54.81	gold quality
Ammon’s horn	UBERON:0001954	53.98	gold quality
cortical plate	UBERON:0005343	51.19	silver quality
caudate nucleus	UBERON:0001873	50.82	gold quality
upper lobe of left lung	UBERON:0008952	50.79	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.24

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

34 targeting CCDC33, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-648	98.64	66.13	553
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-4665-5P	97.91	67.69	1536
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-3661	97.83	67.30	705
HSA-MIR-4715-5P	97.62	67.47	506
HSA-MIR-335-5P	97.10	68.12	1022
HSA-MIR-631	97.05	66.93	602

Literature-anchored findings (GeneRIF, showing 1)

• Data show that CCDC33-dsRED fusion protein co-localized with a known peroxisomal protein, namely PXT1, and showed punctuate intracellular distribution. (PMID:20068295)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccdc33	ENSDARG00000051858
mus_musculus	Ccdc33	ENSMUSG00000037716
rattus_norvegicus	Ccdc33	ENSRNOG00000008219

Protein

Protein identifiers

Coiled-coil domain-containing protein 33 — Q8N5R6 (reviewed: Q8N5R6)

Alternative names: Cancer/testis antigen 61

All UniProt accessions (3): A0A1B0GV97, Q8N5R6, H0YMB8

Isoforms (5)

UniProt ID	Names	Canonical?
Q8N5R6-1	1	yes
Q8N5R6-2	2
Q8N5R6-4	4
Q8N5R6-5	5
Q8N5R6-6	6

RefSeq proteins (3): NP_001274110, NP_079331, NP_877592 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR035892	C2_domain_sf	Homologous_superfamily
IPR039889	CCD33	Family

Pfam: PF00168

UniProt features (22 total): splice variant 7, sequence variant 3, sequence conflict 3, compositionally biased region 3, region of interest 2, coiled-coil region 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N5R6-F1	72.34	0.24

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 56 (showing top): PIT1_Q6, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOCC_MICROBODY, RFX1_01, MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN, OKUMURA_INFLAMMATORY_RESPONSE_LPS, PR_Q2, DUAN_PRDM5_TARGETS, KRAS.600_UP.V1_DN, ZBTB18_TARGET_GENES, ZNF30_TARGET_GENES, ZNF391_TARGET_GENES, ZNF407_TARGET_GENES, ZNF423_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): peroxisome (GO:0005777)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
microbody	1

Protein interactions and networks

STRING

1663 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC33	UBL7	Q96S82	629
CCDC33	DRC7	Q8IY82	561
CCDC33	CFAP157	Q5JU67	470
CCDC33	ISLR2	Q6UXK2	451
CCDC33	RIBC2	Q9H4K1	449
CCDC33	SMARCB1	Q12824	434
CCDC33	CFAP184	Q2M329	421
CCDC33	LMAN1L	Q9HAT1	420
CCDC33	GOLGA6A	Q9NYA3	418
CCDC33	CCDC81	Q6ZN84	395
CCDC33	MITD1	Q8WV92	393
CCDC33	SMAD3	P84022	389
CCDC33	CT62	P0C5K7	370
CCDC33	BBS4	Q96RK4	367
CCDC33	CLK3	P49761	366

IntAct

125 interactions, top by confidence:

A	B	Type	Score
MLH1	CCDC33	psi-mi:“MI:0915”(physical association)	0.670
SMAD3	CCDC33	psi-mi:“MI:0915”(physical association)	0.670
CCDC33	SMAD3	psi-mi:“MI:0915”(physical association)	0.670
CCDC33	MLH1	psi-mi:“MI:0915”(physical association)	0.670
	CCDC33	psi-mi:“MI:0915”(physical association)	0.610
CCDC33	GPN3	psi-mi:“MI:0915”(physical association)	0.610
GPN3	CCDC33	psi-mi:“MI:0915”(physical association)	0.610
CCDC33	SNF1	psi-mi:“MI:0915”(physical association)	0.560
CCDC33	YPK2	psi-mi:“MI:0915”(physical association)	0.560
PRP4	CCDC33	psi-mi:“MI:0915”(physical association)	0.560
CCDC33	RAM2	psi-mi:“MI:0915”(physical association)	0.560
CCDC33	GCD7	psi-mi:“MI:0915”(physical association)	0.560
CCDC33	SEC6	psi-mi:“MI:0915”(physical association)	0.560
CCDC33	MUD2	psi-mi:“MI:0915”(physical association)	0.560
RFS1	CCDC33	psi-mi:“MI:0915”(physical association)	0.560
TAE1	CCDC33	psi-mi:“MI:0915”(physical association)	0.560
AIR1	CCDC33	psi-mi:“MI:0915”(physical association)	0.560
CCDC33	YCH1	psi-mi:“MI:0915”(physical association)	0.560
CCDC33	BIT61	psi-mi:“MI:0915”(physical association)	0.560
BTN2	CCDC33	psi-mi:“MI:0915”(physical association)	0.560
CCDC33	ITT1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (236): CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid), CCDC33 (Two-hybrid)

ESM2 similar proteins: A0JM13, A1A4L4, A2RRS8, B0DOB4, D4A039, O00750, O70167, O70173, Q08EC4, Q1LXR6, Q3ULW6, Q3UQI9, Q3V0L5, Q3ZAV8, Q4AC94, Q4G0A6, Q52KB6, Q5DTU0, Q5F479, Q5JV73, Q5SUS0, Q5T0N1, Q5XIR4, Q5XIZ9, Q6IFT4, Q6IRN0, Q6IRU7, Q6P1H6, Q6P4K6, Q6PF55, Q6REY9, Q6ZPF3, Q7TP65, Q7Z2Z1, Q80TQ5, Q80VH0, Q8C008, Q8IWE5, Q8N4X5, Q8N5R6

Diamond homologs: Q3ULW6, Q5XIR4, Q8N5R6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

173 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	132
Likely benign	22
Benign	7

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1703679	GRCh37/hg19 15q24.1-24.2(chr15:74398068-76054094)	Pathogenic
3892576	NM_001199040.2(STRA6):c.45G>A (p.Trp15Ter)	Likely pathogenic

SpliceAI

3062 predictions. Top by Δscore:

Variant	Effect	Δscore
15:74244144:GTGGT:G	donor_gain	1.0000
15:74244145:TGGT:T	donor_gain	1.0000
15:74244146:GGTG:G	donor_gain	1.0000
15:74244146:GGTGT:G	donor_loss	1.0000
15:74244147:GT:G	donor_gain	1.0000
15:74244147:GTGT:G	donor_loss	1.0000
15:74244149:G:GG	donor_gain	1.0000
15:74266676:A:AG	acceptor_gain	1.0000
15:74266676:A:C	acceptor_loss	1.0000
15:74266676:AGAT:A	acceptor_gain	1.0000
15:74266677:G:GA	acceptor_gain	1.0000
15:74266677:GA:G	acceptor_gain	1.0000
15:74266677:GAT:G	acceptor_gain	1.0000
15:74266677:GATG:G	acceptor_gain	1.0000
15:74266677:GATGT:G	acceptor_gain	1.0000
15:74266785:AAG:A	donor_gain	1.0000
15:74266785:AAGGT:A	donor_loss	1.0000
15:74266787:GG:G	donor_loss	1.0000
15:74266789:T:A	donor_loss	1.0000
15:74268457:AGG:A	donor_loss	1.0000
15:74271697:CTCCA:C	acceptor_loss	1.0000
15:74271698:TCCA:T	acceptor_loss	1.0000
15:74271699:CCA:C	acceptor_loss	1.0000
15:74271701:A:AG	acceptor_gain	1.0000
15:74271701:A:G	acceptor_loss	1.0000
15:74271702:G:GT	acceptor_gain	1.0000
15:74271702:GAT:G	acceptor_gain	1.0000
15:74271702:GATC:G	acceptor_gain	1.0000
15:74271702:GATCT:G	acceptor_gain	1.0000
15:74271787:GAATT:G	donor_gain	1.0000

AlphaMissense

4931 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000019677 (15:74228591 G>T), RS1000058120 (15:74254448 C>A), RS1000066575 (15:74221968 G>A,C), RS1000068947 (15:74260518 T>C), RS1000106241 (15:74329492 A>G), RS1000114292 (15:74252363 A>G), RS1000124938 (15:74267187 A>G), RS1000136287 (15:74209706 A>G,T), RS1000155433 (15:74255486 G>A), RS1000182990 (15:74299765 A>G), RS1000185742 (15:74238809 A>C), RS1000228135 (15:74302551 C>T), RS1000245502 (15:74222154 C>A,T), RS1000248532 (15:74305633 C>T), RS1000288058 (15:74232976 C>T)

Disease associations

OMIM: gene MIM:618525 | disease phenotypes: MIM:601186

GenCC curated gene-disease

Mondo (2): hearing loss disorder (MONDO:0005365), Matthew-Wood syndrome (MONDO:0011010)

Orphanet (1): Matthew-Wood syndrome (Orphanet:2470)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001762_349	Obesity-related traits	3.000000e-06
GCST001762_659	Obesity-related traits	1.000000e-06
GCST002875_114	Diisocyanate-induced asthma	1.000000e-06
GCST004412_7	Craniofacial microsomia	1.000000e-23
GCST006627_9	Diastolic blood pressure	1.000000e-10
GCST007267_110	Systolic blood pressure	3.000000e-11
GCST009085_1	Bacterial meningitis	4.000000e-08
GCST010108_19	Coffee consumption (cups per day)	7.000000e-13
GCST012227_514	Hip circumference adjusted for BMI	6.000000e-09

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0005116	urinary metabolite measurement
EFO:0006995	response to diisocyanate
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure
EFO:0006782	cups of coffee per day measurement
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
C537768	Anophthalmia with pulmonary hypoplasia (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation, affects cotreatment, increases methylation, decreases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
2,4,6-tribromophenol	decreases expression	1
decabromobiphenyl ether	decreases expression	1
sodium arsenite	decreases expression	1
tetrabromobisphenol A	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
cupric chloride	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants	increases expression, increases abundance	1
Atrazine	increases expression	1
Cadmium	increases abundance, decreases expression	1
Copper	decreases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Methapyrilene	increases methylation	1
Silicon Dioxide	decreases expression	1
Smoke	increases abundance, increases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1
Magnetite Nanoparticles	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT00486577	PHASE2/PHASE3	COMPLETED	Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus
NCT00789061	PHASE2/PHASE3	UNKNOWN	Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation
NCT01423409	PHASE2/PHASE3	COMPLETED	Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People
NCT05786378	PHASE2/PHASE3	UNKNOWN	Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT01108601	PHASE1/PHASE2	UNKNOWN	Transtympanic Ringer’s Lactate for the Prevention of Cisplatin Ototoxicity
NCT01621256	PHASE1/PHASE2	COMPLETED	Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
NCT06370351	PHASE1/PHASE2	RECRUITING	A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
NCT06545175	PHASE1/PHASE2	RECRUITING	Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma
NCT07304024	PHASE1/PHASE2	RECRUITING	A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
NCT01109576	EARLY_PHASE1	COMPLETED	Workshops for Veterans With Vision and Hearing Loss